Hikma Pharmaceuticals (LON:HIK) Stock Price Down 14.1% – Time to Sell?

Shares of Hikma Pharmaceuticals PLC (LON:HIK) dropped 14.1% during trading on Thursday . The stock traded as low as GBX 1,522 and last traded at GBX 1,522. Approximately 166,325,172 shares were traded during trading, an increase of 7,989% from the average daily volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HIK. Berenberg Bank cut their price objective on shares of Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research report on Thursday, October 16th. JPMorgan Chase & Co. lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating for the company in a research note on Friday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,600 price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 7th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research report on Tuesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of GBX 2,615.

Hikma Pharmaceuticals Trading Down 14.1%

The stock’s fifty day simple moving average is GBX 1,740.80 and its 200-day simple moving average is GBX 1,898.69. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The firm has a market cap of £3.37 billion, a PE ratio of 9.11, a PEG ratio of 2.38 and a beta of 0.41.

Insider Transactions at Hikma Pharmaceuticals

In other news, insider Laura Balan Balan bought 3,500 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was purchased at an average cost of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah purchased 14,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The shares were purchased at an average price of GBX 1,603 per share, for a total transaction of £224,420. Company insiders own 17.77% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.